Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: a big US approval for BMS; Roche touts its diverse R&D pipeline; Lumakras’s mixed Phase III results in lung cancer; Japan controversy over a COVID-19 antiviral; and GSK's vaccine strategy in India.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 16 September 2022, including: a big US approval for Bristol Myers Squibb Company; Roche Holding AG touts its diverse R&D pipeline; Lumakras’s mixed Phase III results in lung cancer; Japan controversy over a COVID antiviral; and GSK plc's vaccine strategy in India.
This and all our other podcasts are available on the Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "BMS Aims To Unseat Otezla In Psoriasis With US FDA-Approved Sotyktu" - Scrip, 9 Sep, 2022.)
(Also see "Roche Plays Down Reliance On TIGIT And Alzheimer’s Drugs For Growth" - Scrip, 12 Sep, 2022.)
(Also see "Amgen’s Lumakras Efficacy Confirmed In Phase III, But Not As Strong As Phase II" - Scrip, 12 Sep, 2022.)
(Also see "Japan Physician Groups' Controversial Push For Xocova Backfires" - Scrip, 8 Sep, 2022.)
(Also see "GSK Eases Cervarix Out Of India, Eyes On Trajectory Of Synflorix" - Scrip, 12 Sep, 2022.)